The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
|
|---|---|
| Published in |
Frontiers in oncology, March 2016
|
| DOI | 10.3389/fonc.2016.00069 |
| Pubmed ID | |
| Authors |
Simon J. A. van Kuijk, Ala Yaromina, Ruud Houben, Raymon Niemans, Philippe Lambin, Ludwig J. Dubois |
| Abstract |
Hypoxia is a characteristic of many solid tumors and an adverse prognostic factor for treatment outcome. Hypoxia increases the expression of carbonic anhydrase IX (CAIX), an enzyme that is predominantly found on tumor cells and is involved in maintaining the cellular pH balance. Many clinical studies investigated the prognostic value of CAIX expression, but most have been inconclusive, partly due to small numbers of patients included. The present meta-analysis was therefore performed utilizing the results of all clinical studies to determine the prognostic value of CAIX expression in solid tumors. Renal cell carcinoma was excluded from this meta-analysis due to an alternative mechanism of upregulation. 958 papers were identified from a literature search performed in PubMed and Embase. These papers were independently evaluated by two reviewers and 147 studies were included in the analysis. The meta-analysis revealed strong significant associations between CAIX expression and all endpoints: overall survival [hazard ratio (HR) = 1.76, 95% confidence interval (95%CI) 1.58-1.98], disease-free survival (HR = 1.87, 95%CI 1.62-2.16), locoregional control (HR = 1.54, 95%CI 1.22-1.93), disease-specific survival (HR = 1.78, 95%CI 1.41-2.25), metastasis-free survival (HR = 1.82, 95%CI 1.33-2.50), and progression-free survival (HR = 1.58, 95%CI 1.27-1.96). Subgroup analyses revealed similar associations in the majority of tumor sites and types. In conclusion, these results show that patients having tumors with high CAIX expression have higher risk of locoregional failure, disease progression, and higher risk to develop metastases, independent of tumor type or site. The results of this meta-analysis further support the development of a clinical test to determine patient prognosis based on CAIX expression and may have important implications for the development of new treatment strategies. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 20% |
| Unknown | 4 | 80% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Scientists | 2 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 98 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| South Africa | 1 | 1% |
| Unknown | 97 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 20 | 20% |
| Researcher | 17 | 17% |
| Student > Master | 8 | 8% |
| Student > Bachelor | 7 | 7% |
| Student > Postgraduate | 6 | 6% |
| Other | 15 | 15% |
| Unknown | 25 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 26% |
| Biochemistry, Genetics and Molecular Biology | 16 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 8% |
| Chemistry | 8 | 8% |
| Agricultural and Biological Sciences | 7 | 7% |
| Other | 4 | 4% |
| Unknown | 30 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 May 2016.
All research outputs
#15,421,981
of 26,150,873 outputs
Outputs from Frontiers in oncology
#4,324
of 22,908 outputs
Outputs of similar age
#157,217
of 317,095 outputs
Outputs of similar age from Frontiers in oncology
#29
of 89 outputs
Altmetric has tracked 26,150,873 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,908 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,095 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 89 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.